Comparative Pharmacology
Head-to-head clinical analysis: MVC PLUS versus ZINC SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MVC PLUS versus ZINC SULFATE.
MVC PLUS vs ZINC SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
Zinc sulfate provides essential zinc, a cofactor for over 300 enzymes involved in cell division, DNA synthesis, immune function, and wound healing. It stabilizes cell membranes and has antioxidant properties.
10 mg orally once daily.
For zinc deficiency: 220 mg (containing 50 mg elemental zinc) orally three times daily. For maintenance: 110 mg (25 mg elemental zinc) orally once daily.
None Documented
None Documented
Clinical Note
moderateZinc sulfate + Dolutegravir
"The serum concentration of Dolutegravir can be decreased when it is combined with Zinc sulfate."
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
The terminal elimination half-life of zinc sulfate is approximately 2.5-3 hours in normal subjects; however, the whole-body turnover half-life is considerably longer (12-14 days), reflecting redistribution from exchangeable pools.
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Zinc is primarily excreted in feces (approximately 90%) via biliary and pancreatic secretions, with renal excretion accounting for about 2-10% of total elimination. Minor amounts are lost in sweat and sloughed intestinal cells.
Category C
Category C
Multivitamin/Mineral Supplement
Mineral Supplement